Novel therapies are needed for myelofibrosis (MF), particularly after Janus kinase (JAK) inhibitor failure. This open-label, phase 1/2 study evaluated bomedemstat, an irreversible inhibitor of lysine-specific demethylase 1, in participants with MF refractory or resistant to, inadequately controlled by, or intolerant of approved therapies. Eighty-nine participants initially received bomedemstat at doses 0.25, 0.5, or 0.6 mg/kg orally once per day, titrated to achieve a target platelet count of ≥50 × 109/L to ≤75 × 109/L. Primary end points were safety and change in spleen volume. Hematologic response and change in symptom burden, bone marrow fibrosis score, and variant allele frequency (VAF) were exploratory. Eighty-seven (97%) participants experienced ≥1 any-cause adverse event (AE), most commonly thrombocytopenia (48%) and dysgeusia (36%); 62 (69%) participants experienced ≥1 grade 3 to 5 AE. Three participants (3%) experienced AEs that led to death; none were related to treatment. Of 35 participants with spleen volume data at week 24, 23 (66%) had a reduction in spleen volume; 9 (26%) had a reduction of ≥20%. Mean platelet and white blood cell counts normalized over 24 weeks; hemoglobin levels remained stable. Participants reported improvement in most symptoms, including fatigue. Of 35 participants with baseline and week 24 data, 8 (23%) had improved bone marrow fibrosis by ≥1 grade per central review, and 21 (60%) were stable. Of 36 participants with CALR, JAK2, or MPL mutations and data at week 24, 56% had a reduction in VAF. Bomedemstat had manageable safety and clinical activity in participants with MF in need of an alternative therapy. This trial was registered at www.ClinicalTrials.gov as NCT03136185.

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study / Gill, H., Yacoub, A., Gerds, A.T., Shortt, J., Rossetti, J.M., Mead, A.J., Göthert, J.R., Koschmieder, S., Ewing, J., Halpern, A.B., Palandri, F., Passamonti, F., Mesa, R., Marchetti, M., Harrison, C., Vannucchi, A.M., Watts, J.M., Wood, J.C., Ross, D.M., Peppe, J., et al.. - In: BLOOD ADVANCES. - ISSN 2473-9529. - ELETTRONICO. - 10:(2026), pp. 4585-4594. [10.1182/bloodadvances.2025018141]

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study

Palandri, Francesca;Vannucchi, Alessandro M.;
2026

Abstract

Novel therapies are needed for myelofibrosis (MF), particularly after Janus kinase (JAK) inhibitor failure. This open-label, phase 1/2 study evaluated bomedemstat, an irreversible inhibitor of lysine-specific demethylase 1, in participants with MF refractory or resistant to, inadequately controlled by, or intolerant of approved therapies. Eighty-nine participants initially received bomedemstat at doses 0.25, 0.5, or 0.6 mg/kg orally once per day, titrated to achieve a target platelet count of ≥50 × 109/L to ≤75 × 109/L. Primary end points were safety and change in spleen volume. Hematologic response and change in symptom burden, bone marrow fibrosis score, and variant allele frequency (VAF) were exploratory. Eighty-seven (97%) participants experienced ≥1 any-cause adverse event (AE), most commonly thrombocytopenia (48%) and dysgeusia (36%); 62 (69%) participants experienced ≥1 grade 3 to 5 AE. Three participants (3%) experienced AEs that led to death; none were related to treatment. Of 35 participants with spleen volume data at week 24, 23 (66%) had a reduction in spleen volume; 9 (26%) had a reduction of ≥20%. Mean platelet and white blood cell counts normalized over 24 weeks; hemoglobin levels remained stable. Participants reported improvement in most symptoms, including fatigue. Of 35 participants with baseline and week 24 data, 8 (23%) had improved bone marrow fibrosis by ≥1 grade per central review, and 21 (60%) were stable. Of 36 participants with CALR, JAK2, or MPL mutations and data at week 24, 56% had a reduction in VAF. Bomedemstat had manageable safety and clinical activity in participants with MF in need of an alternative therapy. This trial was registered at www.ClinicalTrials.gov as NCT03136185.
2026
10
4585
4594
Goal 3: Good health and well-being
Gill, Harinder; Yacoub, Abdulraheem; Gerds, Aaron T.; Shortt, Jake; Rossetti, James M.; Mead, Adam J.; Göthert, Joachim R.; Koschmieder, Steffen; Ewin...espandi
File in questo prodotto:
File Dimensione Formato  
main (1).pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 343.46 kB
Formato Adobe PDF
343.46 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1500289
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact